{"name":"ARTHEx Biotech S.L.","slug":"arthex-biotech-s-l","ticker":"","exchange":"","domain":"","description":"ARTHEx Biotech S.L. is a biotechnology company focused on developing innovative therapies. The company's lead candidate, ATX-01, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ATX-01","genericName":"ATX-01","slug":"atx-01","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ATX-01","genericName":"ATX-01","slug":"atx-01","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxOeGRUQ04wa29VRWs2Q3I3RjRNRkRCV2I0dmtYelZyZkFMWWtYX0JkdDBqYm5ISEw5bmMybnVWM2lIQUowMVAtaVlJT1pLb1VnYllrR1FveEg4NHhjaFhsMXNvZmxGbTRNWUszMGQ4UjhXSjBpb2JMZ1U1TUVscGNQR3k5OUZKMk5HdWxNVFRwNjdYOWRkOE5BZVhVM0JoNmU3N05TN2xSWk5vTVlnNGx5LWlIRkE1cGhSemdpaV8yaFlnbzVYQ0NIQk11UFk4YnplTzJ2d2ZOOG94QzNEQWM3RGhZQ1NNekp5c3d6NUZ2Ujg3SWZvQjVFaTJvOA?oc=5","date":"2026-03-11","type":"regulatory","source":"PR Newswire","summary":"ARTHEx Biotech Granted FDA Fast Track Designation for ATX-01 for the Treatment of Myotonic Dystrophy Type 1 (DM1) - PR Newswire","headline":"ARTHEx Biotech Granted FDA Fast Track Designation for ATX-01 for the Treatment of Myotonic Dystrophy Type 1 (DM1)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gJBVV95cUxOOG10dHljeDJsbDhfNVlJR24ybTFVb1NOM21ZZndmR0l0OXNuV3pRTnlGblRFZDE1TGVkSzdsMGJOcDBpUEw0X3ZIZnRtamxsOUpmRWp5V2laMS1zbEZ4bUJhaG5mbVdkSjRnNHEwU0ZpZG0yOUVkQWVldFNhc3lSS2xaN0JpS21kQUN0Mm1TMFEzaTJNRk0tcEJXbjdNRk5pbFRBY0JwTGF6dnAyQTJBWnpRb2N1R1dWS3NXbWpXR20taDVNOVpfUnJnTkJ0ckpRdWVNM2plSmJDYk5xejNBTDZ3NGlPZVRZWFJDQ0RlRzVmV0NXWXJ4QThGckxySHhzeUtpeGZmT3hTWE9UdXg3SUhBT05WQ1JzTU9QWXdkYlp1bk9DR2JIM2JsYmsxTXpOQkx0X0ZBX3JyRl9GaDV3ZE1pN3d1YjNYQmtoY3U2S1VIcTRmaVhFcWxvaDJPUQ?oc=5","date":"2026-02-25","type":"pipeline","source":"PR Newswire","summary":"ARTHEx Biotech Announces Publication in The American Journal of Human Genetics Highlighting the Discovery and Preliminary Preclinical Profile of ATX-01 for Myotonic Dystrophy Type 1 (DM1) - PR Newswir","headline":"ARTHEx Biotech Announces Publication in The American Journal of Human Genetics Highlighting the Discovery and Preliminar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNY1BnZFRGMEFtbHdKQW1XdVdub3pPMHBISjRZYnZrNW5GODh6ZGNHMzQ0TkRfQVJhM1k3akNoT3lnYzlrZ2czay1hZFFiZVNBVG1pYkpkRF9IangwRks3eDNFcGxaV1ZfMmZ0b193eldUcERHTnZ3Wkx6eHNxWUlhalNndzBCUTNXQWF2d2FneU5fM2c5Mk8zNTJ5QjJEUnBsQjRQTXRfcGdUbG5veXZaRmlmUVNwMVZZb1BOYVBrUDJOZ2RI?oc=5","date":"2025-10-09","type":"pipeline","source":"PR Newswire","summary":"ARTHEx Biotech to Participate in Upcoming Investor and Industry Events - PR Newswire","headline":"ARTHEx Biotech to Participate in Upcoming Investor and Industry Events","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxNNVp6elU4X2IyRHNMV0kzdFppTUlodXRYR0VaSzJBTG1Sd2E2dGQ5OUI4YkVfMVBaZ1JNNndVZTY5WHBVLUc0dW5aTVo2UE51QW5aeU9TcWUtbEY2MEpEOFY2NjlyMXZjWXg0UmZqM1paaGlpQlFsQnJGaTE4R1IwN1FXUVN6LTYwTFA1N1NudWF4Mzh2N2JaZDJ6QWFRaEU0QVB4QmE1SC1JVEZHNS1SQ0UtcXAwOTE4dUdwN2VrS3QyX2xGakt5RTBxQTNxRnlHMVBvQnRocHpuamM3TUhkQ1V0LWdJWVJPNUVMYUNMcUttT3ZEdVZiQXN0VWRPQk85N1VueGRxbGM3REN1Nk5NVmxYTGM0N0FUVDcwOFhKcGRkdXJiSi1xM2EzMnZTRGk5Y2F2VjBBU2ppMWlX?oc=5","date":"2025-09-17","type":"pipeline","source":"PR Newswire","summary":"ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines - PR Newswire","headline":"ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPYVRXZ3U0TGF3NTNmUTRNcHJrb2pzeXpjQ2d2c2szazUweW5oczVuaFkyUk92Q0E4VXFBVmlHUXJvMUJ3RzQ5WUpGeTRzVl83ZWxBV1QyWFo3ZThQTHdFcXI5Rmx6QnRacWdwZVpQcG81Vmo0QTBCb1JWOVJuSmFpOUh6a21EdlpUZ2dkbjBjcnVleFZIOEZWSXo0V2RNSzdEWnA1VmpDQUo0YUpFcnNnTmhNbkJtNmhKRXhHbnpSV2NZSEpDaFRqaXFVZ0Q0ZFN2dzcxTkFlNU1odw?oc=5","date":"2025-03-27","type":"pipeline","source":"PR Newswire","summary":"ARTHEx Biotech to Participate in the 24th Annual Needham Virtual Healthcare Conference - PR Newswire","headline":"ARTHEx Biotech to Participate in the 24th Annual Needham Virtual Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxQaHAweXUwLXpfTXF1RFdVaUJ1M196ajJ6OEV4eVRyNXJmdXJMbldMU3dod3k2b0h1TUJ6VW9YUERxQXBEMno0WW9faVc0Tl9UaWMwU1hNZ2NSRVNwVk82NVpGckRGV2tXRGdGcVlRUFQ1dlFxYnJqaDM5X19xXzVhTWJ0aTY3WUhlZ1ptVmJYTThIYUh1VTJEcEQ1NE5oUlhmN1dBdjRfMTVQUm5OdUFka0JIZ243X2V1M0FwenVrWU1XQ3dlR3IzMGF3V0JDQi1LbGZ4eFFkUnhBSnd0QTJUcENrelhkczR3bzlqWmJTX3VpM3lCaFlUaEVVMnhERWdRbTFScFlSbHdYWnRsX3FYbEdUTQ?oc=5","date":"2024-11-27","type":"trial","source":"PR Newswire","summary":"Myotonic Dystrophy Clinical Trial Pipeline Boom as Over 20 Companies Leading the Charge in Research and Development | DelveInsight - PR Newswire","headline":"Myotonic Dystrophy Clinical Trial Pipeline Boom as Over 20 Companies Leading the Charge in Research and Development | De","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxNSWEwSjl5OHliVVhmLW9VZjBrckxxTXBLRmpOS0o0bjhjZ1dsQTVKWWJYbnpmTnh4R0xpenJwMGdMRG5DZUZQYVdvMlkwOWhZZDhBaTZFSTc4dkFpRGhpSDZHcFR0T0U2OHZfUmNNN01CaUxULXo3RXhaeHNGQ2RSOWIwdUM3bElIUlJqM1BJNnV0eHFKSVNvVXZ2Vk55OFVENkY2VGl0Zm1LOE9ub3YyR2ZfS3BsOVh0SjJ0YmxmV3V5bmNvaGZRNkt2OEhLUXJ3WlZ5N1VwSHRYb3Z5aGc2SUZuaTFmWmppZ0k3NUIweWhxN2ZheDlR?oc=5","date":"2024-10-18","type":"trial","source":"PR Newswire","summary":"ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1) - PR Newswire","headline":"ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNQm9vT013UVBaQjBKcEZ3aDIwQl9yWmV4anFnZHZXRlRzSUtqOHhOZ0pCR24xWHJ4ZlctZHFHX3k1LWdqcnlsVTJIakQwVlIxcU9yWDQ0Z3c2WmhpWGhySEEwaHN0UW0wanVHMUZIeU05T2p0TWVQOVUyWklNZmJDS3JaLWVwOXNSSDlxYXdTcVFCX3dFUFY2MXBmSGFGZC1BWXNHbS1ORE9CcGNqUmk5ZmRHUVRWTHRsaXlSejdacl93Y1h2eXA1TFlMTQ?oc=5","date":"2022-10-25","type":"pipeline","source":"PR Newswire","summary":"Arthex Biotech Selected for EIC Accelerator Award of up to 14 Million Euros - PR Newswire","headline":"Arthex Biotech Selected for EIC Accelerator Award of up to 14 Million Euros","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}